Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Izotropic ( (TSE:IZO) ) has issued an update.
Izotropic Corporation has signed a letter agreement with a business group to create Izotropic Africa, a Casablanca-based entity that will license, market, and distribute the IzoView Breast CT system and follow-on products across Africa and the Gulf Cooperation Council states. The move targets a rapidly growing regional market for advanced oncology imaging, where breast cancer incidence is high and mortality rates are elevated due to late diagnosis and limited access to sophisticated diagnostic tools.
Under the agreement, the business group will hold 60% of the new entity and Izotropic 40%, with both parties aiming to finalize a formal contract by April 30, 2026. The partners plan to secure a major Moroccan hospital by the first quarter of 2026 as a site for installing the first IzoView system for research, data collection, and regulatory approvals, while also evaluating local manufacturing or assembly, a strategy that could significantly extend Izotropic’s operational footprint and long-term revenue opportunities in Africa and the GCC.
The business group will lead annual business planning and engage with regional health ministries to initiate approval processes, anchoring market entry and regulatory pathways for IzoView and future products. Izotropic will provide technical, clinical, and operational support and has agreed to advance $30,000 toward an estimated first-year startup budget, with any further funding and commitments contingent on executing a formal agreement and securing financing.
The most recent analyst rating on (TSE:IZO) stock is a Hold with a C$0.19 price target. To see the full list of analyst forecasts on Izotropic stock, see the TSE:IZO Stock Forecast page.
Spark’s Take on TSE:IZO Stock
According to Spark, TipRanks’ AI Analyst, TSE:IZO is a Neutral.
The score is mainly pressured by very weak financial performance (no revenue, persistent losses, negative free cash flow, and negative equity). Technical indicators also point to a bearish trend with weak momentum. Valuation provides limited offset since the company is loss-making (negative P/E) and has no dividend yield data.
To see Spark’s full report on TSE:IZO stock, click here.
More about Izotropic
Izotropic Corporation is a medical device company focused on commercializing imaging-based technologies to improve the screening, diagnosis, and treatment of breast cancer. Its core product, the IzoView Breast CT system, targets markets where access to advanced breast imaging is limited, positioning the company to serve unmet oncology and diagnostic needs globally.
Average Trading Volume: 38,353
Technical Sentiment Signal: Sell
Current Market Cap: C$14.57M
Learn more about IZO stock on TipRanks’ Stock Analysis page.